Expertise in
24
conditions

Dr. Naveed A. Wagle

Neurology
2125 Arizona Avenue, Floor 2, 
Santa Monica, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
24
conditions
2125 Arizona Avenue, Floor 2, 
Santa Monica, CA 

Overview

Naveed Wagle is a Neurologist practicing medicine in Santa Monica, California.

Dr. Wagle is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Astrocytoma, Glioblastoma, Glioma, and Gliosarcoma.

He is actively involved in clinical research, co-authoring 25 peer reviewed articles and participating in 7 clinical trials. Dr. Wagle is currently accepting new patients.

Specialties

Neurology

Licenses

Psychiatry & Neurology in CA

Hospital Affiliations

Saint John's Health Center
Providence Little Company Of Mary Med Ctr Torrance
Providence Saint Joseph Medical Ctr

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

2125 Arizona Avenue, Floor 2, Santa Monica, CA 90404

Additional Areas of Focus

Dr. Wagle has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Enrollment Status: Recruiting
Publish Date: September 02, 2026
Intervention Type: Drug
Study Drugs: Vismodegib, GSK2256098, Capivasertib, Abemaciclib
Study Phase: Phase 2
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
An Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent or Progressive Grade III or Grade IV Gliomas With IDH1 Mutation
An Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent or Progressive Grade III or Grade IV Gliomas With IDH1 Mutation
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2026
Intervention Type: Drug
Study Drug: Perillyl Alcohol
Study Phase: Phase 1/Phase 2
A Phase II Open-label Study Investigating the Efficacy, Safety and Pharmacokinetic Properties of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
A Phase II Open-label Study Investigating the Efficacy, Safety and Pharmacokinetic Properties of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: August 12, 2025
Intervention Type: Drug
Study Drugs: OKN-007, Temozolomide (TMZ)
Study Phase: Phase 2
Phase II Study of Patients With Recurrent Glioblastoma Multiforme Treated With Maximal Safe Neurosurgical Resection and Intra-Operative Radiation Therapy (IORT) Using the Xoft Axxent Electronic Brachytherapy System and Bevacizumab
Phase II Study of Patients With Recurrent Glioblastoma Multiforme Treated With Maximal Safe Neurosurgical Resection and Intra-Operative Radiation Therapy (IORT) Using the Xoft Axxent Electronic Brachytherapy System and Bevacizumab
Enrollment Status: Terminated
Publish Date: April 26, 2024
Intervention Type: Drug, Radiation
Study Drugs: Bevacizumab, Avastin
Study Phase: Phase 2
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: April 03, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
Enrollment Status: Completed
Publish Date: May 11, 2023
Intervention Type: Drug, Radiation
Study Drugs: Temozolomide, Depatuxizumab
Study Phase: Phase 3
View 6 Less Clinical Trials

25 Total Publications

Pre-radiation Nivolumab plus ipilimumab in patients with newly diagnosed high-grade gliomas.
Pre-radiation Nivolumab plus ipilimumab in patients with newly diagnosed high-grade gliomas.
Journal: Oncoimmunology
Published: November 22, 2024
Similar Doctors
Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required

UCLA Health Westwood Neurology

300 UCLA Medical Plz Ste B200, 
Los Angeles, CA 
 (3.0 miles away)
310-794-1195
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Timothy Cloughesy is a Neurologist practicing medicine in Los Angeles, California. Dr. Cloughesy is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required
Before you request
2121 Santa Monica Boulevard, 
Santa Monica, CA 
 (0.4 miles away)
310-829-5511
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Santosh Kesari is a Neurologist practicing medicine in Santa Monica, California. Dr. Kesari is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, Brain Tumor, and Tissue Biopsy. Dr. Kesari is currently accepting new patients.

Expertise in
53
conditions
Expertise in
53
conditions
Referral may be required

Office

300 Medical Plz, 
Los Angeles, CA 
 (3.1 miles away)
310-794-1195
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Susan Perlman is a Neurologist practicing medicine in Los Angeles, California. Dr. Perlman is highly rated in 53 conditions, according to our data. Her clinical expertise encompasses Spinocerebellar Ataxia, Friedreich Ataxia, Drug Induced Dyskinesia, and Olivopontocerebellar Atrophy.

Frequently Asked Questions about Dr. Naveed A. Wagle

How do I make an appointment with Dr. Naveed A. Wagle?

You can book an appointment with Dr. Naveed A. Wagle by calling their office at 310-582-7450. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Naveed A. Wagle a top-rated expert for Astrocytoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Naveed A. Wagle is classified as an Distinguished expert for Astrocytoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Naveed A. Wagle specialize in?

While Dr. Naveed A. Wagle is a Neurology, they have specific expertise in Astrocytoma, Glioblastoma, and Glioma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Naveed A. Wagle participate in research or clinical trials?

Yes. Dr. Naveed A. Wagle has published 25 articles and abstracts on conditions like Astrocytoma. You can view a list of Dr. Naveed A. Wagle's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Naveed A. Wagle accept my insurance?

Dr. Naveed A. Wagle accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 310-582-7450 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wagle's expertise for a condition
ConditionClose
    View All 15 Distinguished Conditions
    View All 9 Advanced Conditions
    View All 42 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile